Mezzasalma Advisors LLC Has $1.54 Million Stock Position in Novo Nordisk A/S (NYSE:NVO)

Mezzasalma Advisors LLC trimmed its position in Novo Nordisk A/S (NYSE:NVO) by 25.6% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 17,861 shares of the company’s stock after selling 6,146 shares during the period. Mezzasalma Advisors LLC’s holdings in Novo Nordisk A/S were worth $1,536,000 as of its most recent filing with the SEC.

Other hedge funds also recently modified their holdings of the company. Natixis Advisors LLC boosted its position in Novo Nordisk A/S by 2.7% during the 3rd quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock worth $366,125,000 after buying an additional 80,070 shares during the period. Norman Fields Gottscho Capital Management LLC grew its position in shares of Novo Nordisk A/S by 45.3% during the 4th quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company’s stock worth $5,482,000 after buying an additional 19,870 shares during the period. Versant Capital Management Inc bought a new stake in shares of Novo Nordisk A/S in the 4th quarter valued at $86,000. Talbot Financial LLC acquired a new position in shares of Novo Nordisk A/S during the 4th quarter valued at $4,066,000. Finally, Clear Creek Financial Management LLC bought a new position in Novo Nordisk A/S during the fourth quarter worth $450,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 0.9 %

NYSE NVO opened at $86.39 on Friday. The company has a current ratio of 0.74, a quick ratio of 0.75 and a debt-to-equity ratio of 0.62. The firm has a market capitalization of $387.66 billion, a P/E ratio of 26.26, a PEG ratio of 0.96 and a beta of 0.45. The business has a fifty day simple moving average of $91.86 and a 200 day simple moving average of $111.83. Novo Nordisk A/S has a 12 month low of $78.17 and a 12 month high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. On average, analysts predict that Novo Nordisk A/S will post 3.86 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The business also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be issued a $0.7874 dividend. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. This represents a dividend yield of 1.2%. The ex-dividend date of this dividend is Monday, March 31st. Novo Nordisk A/S’s payout ratio is 21.88%.

Analysts Set New Price Targets

NVO has been the topic of a number of research analyst reports. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. BMO Capital Markets cut their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, December 23rd. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. Finally, StockNews.com downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Novo Nordisk A/S presently has a consensus rating of “Buy” and an average price target of $145.25.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.